Prostate cancer early detection: A clinical perspective

Epidemiologic Reviews

Volumn 23, Issue 1, 2001, Pages 173-180

  Grossfeld, Gary D ^a   Carroll, Peter R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; EARLY DIAGNOSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0034806814     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a000786     Document Type: Review

References (91)

1. Cancer statistics, 1999
2. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing
3. Interpreting recent trends in prostate cancer incidence and mortality
4. The nature of prostate cancer detected through prostate specific antigen based screening
5. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
6. Population-based prostate cancer trends in the PSA era: Data from the Surveillance, Epidemiology, and End Results (SEER) program
7. Temporal trends in rates of prostate cancer: Declining incidence of advanced stage disease, 1974 to 1994
8. The National Cancer Data Base report on longitudinal observations on prostate cancer
9. Adenocarcinoma of the prostate: Results of routine urological screening
10. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
11. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age
12. Prostate-specific antigen in milk of lactating women
13. Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique
14. Prostate-specific antigen expression by various tumors
15. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
16. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin
17. Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era
18. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels
19. Ejaculation increases the serum prostate-specific antigen concentration
20. The effect of digital rectal examination on the serum prostate specific antigen concentration: Results of a randomized study
21. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
22. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
23. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia
24. Effect of finasteride on prostate-specific antigen density
25. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin
26. Screening for prostate cancer with prostate-specific antigen: An examination of the evidence
27. Prostate cancer detection in a clinical urological practice by ultra-sonography, digital rectal examination and prostate specific antigen
28. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
29. Diagnosis of prostatic carcinoma: The yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography
30. Prostate-specific antigen
31. Systematic sextant biopsies in 651 patients referred for prostate evaluation
32. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
33. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer
34. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients
35. PSA density (PSAD): Role in patient evaluation and management
36. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves
37. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma
38. Prostate specific antigen density of the transition zone for early detection of prostate cancer
39. Total and transition zone prostate volume and age: How do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
40. Influence of patient age on the serum PSA concentration: An important clinical observation
41. Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity
42. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen
43. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer
44. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
45. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age
46. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenter clinical trial
47. Assay variability in serum prostate-specific antigen determination
48. Comparison of 3 investigational assays for the free form of prostate specific antigen
49. Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis
50. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA
51. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen
52. Measurement of complexed PSA improves specificity for early detection of prostate cancer
53. Is complexed PSA alone clinically useful?
54. The appearance of prostate cancer on transrectal ultrasonography: Correlation of imaging and pathological examinations
55. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies
56. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate
57. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate
58. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection
59. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate
60. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer
61. Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated
62. Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection
63. Value of systematic transition zone biopsies in the early detection of prostate cancer
64. Indications for transition zone biopsy in the detection of prostatic carcinoma
65. Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: Who should undergo a repeat biopsy?
66. Follow-up of benign hypoechoic peripheral zone lesions of the prostate gland: US characteristics and cancer prevalence
67. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies
68. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
69. Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy
70. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure
71. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy
72. Morbidity of ultrasound-guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy: A prospective study in 415 cases
73. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: Evaluation of complication rates and risk factors within a population-based screening program
74. Risks and complications of transrectal ultrasound guided prostate needle biopsy: A prospective study and review of the literature
75. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer
76. Longitudinal screening for prostate cancer with prostate-specific antigen
77. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection
78. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial
79. Screening digital rectal examination and prostate cancer mortality: A population-based case-control study
80. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota
81. Implications of stage-specific survival rates in assessing declines in prostate cancer mortality rates
82. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen
83. Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States
84. Future benefits and cost-effectiveness of prostate carcinoma screening
85. An economic rationale for prostate cancer screening
86. An overview cost-utility analysis of prostate cancer screening
87. Informed consent for PSA screening: Does it happen?
88. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges
89. Age-specific reference ranges for prostate-specific antigen in black men
90. Serum prostate-specific antigen in a community-based population of healthy Japanese men: Lower values than for similarly aged white men